Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,264.00
Bid: 12,280.00
Ask: 12,282.00
Change: 146.00 (1.20%)
Spread: 2.00 (0.016%)
Open: 12,244.00
High: 12,384.00
Low: 12,228.00
Prev. Close: 12,118.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Stocks up as protests in China deterred by police

Tue, 29th Nov 2022 08:57

(Alliance News) - The FSTE 100 opened in the green on Tuesday as investors were reassured that civil unrest in China would be short lived amid unyielding action by the authorities.

"Police in China have quashed mass Covid demonstrations for now, helping stocks regain their footing on indices across Asia, setting the tone for a positive open in Europe," said Susannah Streeter at Hargreaves Lansdown.

The FTSE 100 index opened up 64.88 points, 0.9%, at 7,538.90. The FTSE 250 was up 11.98 points, 0.1%, at 19,304.33, while the AIM All-Share was down 1.52 points, or 0.2% at 849.40.

The Cboe UK 100 was up 0.8% at 753.71, the Cboe UK 250 was down 0.2% at 16,700.37, and the Cboe Small Companies was up 0.6% at 13,219.22.

In Europe, the CAC 40 index in Paris was up 0.3% and the DAX 40 in Frankfurt was up 0.1%.

China's major cities of Beijing and Shanghai were blanketed with security in the wake of nationwide rallies calling for political freedoms and an end to Covid lockdowns.

The country's leadership is facing a wave of protest not seen in decades, fuelled by anger over the unrelenting lockdowns as well as deep-rooted frustrations over China's political direction.

With police cars, foot patrols, a network of surveillance cameras, and aided by the icy wind, Beijing authorities appeared to have deterred fresh gatherings.

In semi-autonomous Hong Kong, however, where mass democracy protests erupted in 2019, dozens gathered at the Chinese University to mourn the victims of the Urumqi fire. The demonstrators said Covid restrictions were to blame for hampering rescue efforts of the deadly fire.

As the police cracked down on protesters, stocks in China closed firmly in the green on Tuesday. The Shanghai Composite closed up 2.3%, and the Hang Seng in Hong Kong closed up sharply, ending 5.2% higher.

The Nikkei 225 in Tokyo ended up 0.5% and the S&P/ASX 200 in Sydney closed up 0.3%.

News that China said it would speed up a push to vaccinate people aged 60 and older against Covid-19 also helped to boost Asian stocks and investor confidence elsewhere.

In London, AstraZeneca agreed to acquire Neogene Therapeutics, a clinical stage biotechnology company focused on the discovery, development and manufacturing of T-cell receptor therapies for the treatment of cancer.

AstraZeneca said it will pay up to USD320 million. This will include an initial cash payment of USD200 million upon closing and a further USD120 million, contingent on the meeting of unspecified milestones.

Shares in AstraZeneca were up 0.7%

FTSE 250-listed healthcare sector investor Syncona, which holds an 8% stake in Neogene, said it will receive USD16 million from Astra's initial payment.

Shares in Syncona were up 1.2%.

easyJet reported a "record bounce back" in the year ended September 30, with a sharp rise in annual revenue and a significantly narrowed loss.

The low-cost airline's pretax loss narrowed to GBP208 million from GBP1.04 billion the previous year, as revenue multiplied to GBP5.77 billion from GBP1.46 billion the year prior.

easyJet credited the relaxation of pandemic restrictions and an increase in ancillary products for the revenue rise.

Shares in the airline were down 2.0%.

John Wood Group said its trading in the first ten months of 2022 was in line with its expectations. As a result, the company confirmed its full-year guidance.

It expects annual revenue between USD5.2 billion and USD5.5 billion, with adjusted earnings before interest, tax, depreciation and amortisation around the middle of its guidance range of USD370 million and USD400 million.

The guidance saw John Wood plummet 12% in early morning trade.

Elsewhere, Treatt announced a rise in annual revenue but a fall in profit amid negative impacts from Covid restrictions in China, volatile currency movements, and cost inflation.

In the financial year that ended September 30, the ingredient supplier for the beverage, flavour and fragrance industry reported a pretax profit of GBP16.2 million, down from GBP19.6 million the previous year.

Cost of sales jumped to GBP101.1 million from GBP82.1 million, offsetting revenue which grew to GBP140.2 million from GBP124.3 million.

Shares in Treatt were down 1.6%.

The pound was quoted at USD1.2027 early Tuesday in London, a touch higher from USD1.2025 at the London equities close on Monday. Against the yen, the dollar was trading at JPY138.20, down from JPY138.89.

The euro stood at USD1.0368 shortly after the European equities open on Tuesday morning, lower against USD1.0377 late Monday.

For ING's Francesco Pesole, the key for the US dollar moving forward will be Wednesday's speech by Fed Chair Jerome Powell, in which Pesole sees a "higher likelihood that he will sound hawkish", and US jobs data due on Friday.

This is because this may cause the Fed's "communicated and perceived narrative to drift away from dovish pivot expectations".

Ipek Ozkardeskaya added: "There is still hope that Fed President Jerome Powell talks about slower rate hikes at his speech this week, but again, his words shouldn't be heard halfway through. The Fed is willing to slow the pace of rate hikes to avoid going too far. But if they slow down, it's also because they want to go higher than 5%."

St Louis Federal Reserve President James Bullard affirmed on Monday that he believes the Federal Reserve will need to lift the federal funds rate to at least the bottom of a 5% to 7% range.

The benchmark rate is currently 3.75% to 4.00%.

Bullard's hawkishness was echoed by European Central Bank President Christine Lagarde who also signalled further interest rate hikes to come to come on Monday.

"I would like to see inflation having peaked in October but I'm afraid that I would not go as far as that," Lagarde told European lawmakers in Brussels.

Lagarde said the ECB has been hiking "at the fastest pace ever" and that more increases would be needed to bring inflation back down to the ECB's two-percent target.

"We still have a way to go and we're not done with inflation so, yes, we will continue to raise interest rates," Lagarde said.

Gold fetched USD1,752.70 an ounce, higher against USD1,743.16. Brent oil was quoted at USD85.35 a barrel early Tuesday, up from USD82.84 late Monday.

Still to come on Tuesday, there's a provisional CPI reading from Germany at 1300 GMT.

By Heather Rydings; heatherrydings@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
Today 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
Today 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
Today 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
Today 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
Today 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.